Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H2 2016

  • ID: 4040004
  • Report
  • 36 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Alvogen Korea Co Ltd
  • Esperion Therapeutics Inc
  • Merck & Co Inc
  • MORE
Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H2 2016

Summary:

‘Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H2 2016’, provides in depth analysis on Niemann Pick C1 Like Protein 1 (NPC1L1) targeted pipeline therapeutics.

The report provides comprehensive information on the Niemann Pick C1 Like Protein 1 (NPC1L1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
Certain sections in the report may be removed or altered based on the availability and relevance of data.
Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Niemann Pick C1 Like Protein 1 (NPC1L1)
- The report reviews Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Niemann Pick C1 Like Protein 1 (NPC1L1) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Niemann Pick C1 Like Protein 1 (NPC1L1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Niemann Pick C1 Like Protein 1 (NPC1L1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alvogen Korea Co Ltd
  • Esperion Therapeutics Inc
  • Merck & Co Inc
  • MORE
Introduction

Niemann Pick C1 Like Protein 1 (NPC1L1) Overview

Therapeutics Development

Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Stage of Development

Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Therapy Area

Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Indication

Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Niemann Pick C1 Like Protein 1 (NPC1L1) - Products under Development by Companies

Niemann Pick C1 Like Protein 1 (NPC1L1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Niemann Pick C1 Like Protein 1 (NPC1L1) - Companies Involved in Therapeutics Development

Alvogen Korea Co Ltd

Chong Kun Dang Pharmaceutical Corp

Esperion Therapeutics Inc

Kotobuki Pharmaceutical Co Ltd

Merck & Co Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Niemann Pick C1 Like Protein 1 (NPC1L1) - Drug Profiles

(atorvastatin calcium + ezetimibe) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(atorvastatin calcium + ezetimibe) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(bempedoic acid + ezetimibe) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ezetimibe + rosuvastatin calcium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HS-25 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KT-6971 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Niemann Pick C1 Like Protein 1 (NPC1L1) - Dormant Projects

Niemann Pick C1 Like Protein 1 (NPC1L1) - Featured News & Press Releases

Feb 15, 2016: Merck Receives Complete Response Letter from the U.S. FDA for ZETIA (ezetimibe)

Jan 14, 2014: Merck Voluntarily Recalls All Lots of LIPTRUZET in the United States From Wholesalers Due to Packaging Defects

May 03, 2013: Merck Gets FDA Approval For Liptruzeta For Treatment Of Primary Or Mixed Hyperlipidemia

Jan 02, 2013: Merck Announces FDA Acknowledgement Of Resubmission Of New Drug Application For Ezetimibe/Atorvastatin Tablets

Apr 04, 2012: Frontage Successfully Files IND To Launch US Statin Study

Mar 05, 2012: Merck Provides U.S. Regulatory Update on Investigational Ezetimibe/Atorvastatin Tablets

Nov 03, 2009: FDA Turns Down Merck's Application For Combo Cholesterol Pill Involving Lipitor

Mar 27, 2007: Merck And Schering To Develop Zetia/Lipitor Combo As Focus On Reducing Bad Cholesterol Returns

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Alvogen Korea Co Ltd, H2 2016

Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016

Pipeline by Esperion Therapeutics Inc, H2 2016

Pipeline by Kotobuki Pharmaceutical Co Ltd, H2 2016

Pipeline by Merck & Co Inc, H2 2016

Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2016

Dormant Projects, H2 2016

List of Figures:

Number of Products under Development for, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alvogen Korea Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Esperion Therapeutics Inc
  • Kotobuki Pharmaceutical Co Ltd
  • Merck & Co Inc
  • Zhejiang Hisun Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll